The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback